STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRDF
  4. [Form 4] Cardiff Oncology, Inc. Insider Trading Activity

Director James O. Armitage awarded 40,565 Cardiff Oncology (CRDF) stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cardiff Oncology, Inc. director James O. Armitage was granted stock options covering 40,565 shares of common stock. The options have an exercise price of $1.59 per share and expire on June 11, 2036. After this award, he holds 228,104 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Armitage James O
Role null
Type Security Shares Price Value
Grant/Award Stock Options 40,565 $0.00 --
Holdings After Transaction: Stock Options — 228,104 shares (Direct, null)
Footnotes (1)
Stock options granted 40,565 options Grant to director on June 11, 2026
Exercise price $1.59 per share Conversion or exercise price of options
Expiration date June 11, 2036 Option term end for granted stock options
Derivative holdings after grant 228,104 securities Total derivative securities held directly after transaction
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: "2036-06-11T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Armitage James O
(Last)(First)(Middle)
11055 FLINTKOTE AVE
C/O CARDIFF ONCOLOGY, INC.
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options$1.5906/11/2026A40,56506/11/202706/11/2036Common Stock40,565$0228,104D
Explanation of Responses:
/s/ James Armitage06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cardiff Oncology (CRDF) report for James O. Armitage?

Cardiff Oncology director James O. Armitage received a grant of stock options for 40,565 shares of common stock. This was a compensation-related award, not an open-market purchase or sale, and increases his derivative holdings tied to the company’s stock.

What is the exercise price of the new Cardiff Oncology (CRDF) stock options?

The granted stock options have an exercise price of $1.59 per share. This is the price at which James O. Armitage can buy Cardiff Oncology common stock under the award during the option term, subject to any vesting conditions not detailed here.

When do James O. Armitage’s new Cardiff Oncology (CRDF) options expire?

The stock options granted to James O. Armitage expire on June 11, 2036. This long-dated expiration gives him a multi-year period to potentially exercise the options at $1.59 per share if conditions for exercise are met in the future.

How many Cardiff Oncology (CRDF) derivative securities does James O. Armitage hold after this grant?

Following the option grant, James O. Armitage holds 228,104 derivative securities. This figure reflects his direct derivative position, including the newly awarded 40,565 stock options linked to Cardiff Oncology common shares, as reported in the transaction details.

Was this Cardiff Oncology (CRDF) insider transaction a market buy or sell?

No, this was not a market buy or sell. The transaction is classified as a grant or award acquisition of stock options, meaning the director received options as compensation rather than trading Cardiff Oncology shares in the open market.